Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: A retrospective analysis

The Kaohsiung Journal of Medical Sciences - Tập 33 - Trang 609-615 - 2017
Ming-Xiong Sheng1, Ling-Ling Wan1, Chang-Ming Liu1, Chun-Xiao Liu2, Shu-Shang Chen3
1Department of Urology, Mindong Hospital Affiliated to Fujian Medical University, Fuan, Fujian, People's Republic of China
2Department of Urology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guang Dong, People's Republic of China
3Department of Urology, Fuzhou General Hospital, Xiamen University, Fuzhou, Fujian, People's Republic of China

Tóm tắt

Abstract

The current study is a retrospective analysis of 49 patients with bone metastatic prostate cancer: 26 receiving androgen deprivation therapy (ADT) alone versus 23 receiving cytoreductive cryosurgery of the primary tumor plus ADT treatment. Progression‐free survival (PFS) was the primary outcome variable, and Cox proportional hazards regression analysis was used to identify predictors for PFS. The baseline characteristics were generally comparable between the 2 groups. Median follow‐up time was 41 months (range 24–56) and 37 months (range 19–53) in ADT alone group and cryosurgery groups, respectively. Patients receiving cryosurgery had significantly longer PFS (35 vs 25 months, P = 0.0027) and time to castration resistance (36 vs 25 months, P = 0.0011). Cox multivariate analysis associated longer PFS with the following factors: cryosurgery (HR0.207, 95% CI 0.094–0.456), lower prostate specific antigen at diagnosis (≤100 ng/ml, HR0.235, 95% CI 0.072–0.763) and lower Gleason score (≤7, HR0.195, 95% CI 0.077–0.496). Cryosurgery reduced the risk of progression by 79.3%. In conclusion, cytoreductive cryosurgery of the primary tumor in patients with bone metastatic prostate cancer could reduce the risk of progression and delay time to castration‐resistant prostate cancer.


Tài liệu tham khảo

10.1016/j.eururo.2013.11.002 10.1111/bju.12169 10.1016/j.juro.2014.09.089 10.1016/j.eururo.2014.08.056 10.1016/j.eururo.2013.11.012 Sverrisson E., 2013, Cryosurgery for prostate cancer: a comprehensive review, Arch Esp Urol, 66, 546 Al Ekish S., 2013, The role of cryosurgery of the prostate for nonsurgical candidates, JSLS, 17, 423, 10.4293/108680813X13693422518551 10.1016/j.prnil.2015.02.006 10.1016/j.juro.2012.06.014 10.1111/bju.12512 10.1111/bju.12476 10.1016/j.eururo.2013.09.046 10.1016/j.juro.2015.02.084 10.4111/kju.2014.55.12.780 10.7326/0003-4819-148-6-200803180-00209 Govorov A.V., 2014, Treatment of prostate cancer using cryoablation: a prospective study, Urologiia, 6, 69 10.1097/MOU.0b013e32831e16ce Govorov A.V., 2015, Quality of life in patients undergoing prostate cryoablation, Urologiia, 3, 43 10.1038/nrc2621 10.1016/j.cell.2009.11.025 10.1073/pnas.1320565110 10.1016/j.cryobiol.2008.10.126 10.1016/j.cryobiol.2008.06.003 10.1158/1078-0432.CCR-04-2422 10.1038/sj.jid.5700777 10.1006/cryo.2001.2305 10.1158/1078-0432.CCR-06-1840 10.1016/j.eururo.2009.02.016 10.1002/cncr.24283 10.1111/j.1532-5415.2008.02091.x